牛牛AI助手已提取核心信息
AbbVie Inc., a biopharmaceutical company, has successfully completed the acquisition of ImmunoGen, Inc., a leader in antibody-drug conjugates for cancer treatment, as of February 12, 2024. This follows the Merger Agreement entered into on November 30, 2023. In accordance with the terms of the Merger Agreement, AbbVie has assumed the ImmunoGen Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen Inducement Equity Incentive Plan, as amended. Outstanding restricted stock unit awards under these plans have been converted into awards for AbbVie common stock. The company has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission to register the common stock issuable upon the settlement of the converted awards. This move is part of AbbVie's strategic efforts to expand its oncology portfolio and leverage ImmunoGen's expertise in the development of targeted therapies for cancer patients.
AbbVie Inc., a biopharmaceutical company, has successfully completed the acquisition of ImmunoGen, Inc., a leader in antibody-drug conjugates for cancer treatment, as of February 12, 2024. This follows the Merger Agreement entered into on November 30, 2023. In accordance with the terms of the Merger Agreement, AbbVie has assumed the ImmunoGen Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen Inducement Equity Incentive Plan, as amended. Outstanding restricted stock unit awards under these plans have been converted into awards for AbbVie common stock. The company has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission to register the common stock issuable upon the settlement of the converted awards. This move is part of AbbVie's strategic efforts to expand its oncology portfolio and leverage ImmunoGen's expertise in the development of targeted therapies for cancer patients.
截至2024年2月12日，生物制药公司艾伯维公司已成功完成对癌症治疗抗体药物偶联物的领导者ImmunoGen, Inc. 的收购。这是继2023年11月30日签订的合并协议之后发生的。根据合并协议的条款，艾伯维接管了ImmunoGen修正和重述的2018年员工、董事和顾问股权激励计划以及经修订的ImmunoGen激励股权激励计划。这些计划下未偿还的限制性股票单位奖励已转换为艾伯维普通股的奖励。该公司已向美国证券交易委员会提交了S-8表格的注册声明，要求在结算转换后的奖励后注册可发行的普通股。此举是艾伯维战略努力的一部分，旨在扩大其肿瘤学产品组合，并利用ImmunoGen在为癌症患者开发靶向疗法方面的专业知识。
截至2024年2月12日，生物制药公司艾伯维公司已成功完成对癌症治疗抗体药物偶联物的领导者ImmunoGen, Inc. 的收购。这是继2023年11月30日签订的合并协议之后发生的。根据合并协议的条款，艾伯维接管了ImmunoGen修正和重述的2018年员工、董事和顾问股权激励计划以及经修订的ImmunoGen激励股权激励计划。这些计划下未偿还的限制性股票单位奖励已转换为艾伯维普通股的奖励。该公司已向美国证券交易委员会提交了S-8表格的注册声明，要求在结算转换后的奖励后注册可发行的普通股。此举是艾伯维战略努力的一部分，旨在扩大其肿瘤学产品组合，并利用ImmunoGen在为癌症患者开发靶向疗法方面的专业知识。
有用
没用